Everolimus in combination with octreotide LAR as the first-line treatment for advanced neuroendocrine tumors: A phase II trial of the I.T.M.O. (Italian Trials in Medical Oncology) group.

Authors

null

Emilio Bajetta

Istituto di Oncologia, Policlinico di Monza, Monza, Italy

Emilio Bajetta , Laura Catena , Nicola Fazio , Sara Pusceddu , Pamela Biondani , Giusi Blanco , Sergio Ricci , Michele Aieta , Francesca Pucci , Monica Valente , Nadia Bianco , Fernanda Bellomo , Chiara Mauri , Pasquale Buonandi , Vincenza Roberto

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Neuroendocrine/Carcinoid

Clinical Trial Registration Number

2008-007153-13

Citation

J Clin Oncol 31, 2013 (suppl; abstr 4136^)

DOI

10.1200/jco.2013.31.15_suppl.4136

Abstract #

4136^

Poster Bd #

30F

Abstract Disclosures